Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Chronic Heart Failure

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 165 articles:
HTML format



Single Articles


    June 2025
  1. GUO X, Huang C, Zhang L, Hu G, et al
    Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF.
    Circulation. 2025;151:1651-1666.
    PubMed     Abstract available


  2. PANDEY A, Thomas T, Ji Y, Kroger B, et al
    TET2-Mutant Clonal Hematopoiesis Promotes Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:1622-1625.
    PubMed    


  3. FONSEKA O, Raja R, Ross C, Gare SR, et al
    XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity.
    Circulation. 2025;151:1583-1605.
    PubMed     Abstract available


    May 2025
  4. ZHENG Y, Cao Y, Wang W, Tong Y, et al
    Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart Failure.
    Circulation. 2025 May 13. doi: 10.1161/CIRCULATIONAHA.125.074353.
    PubMed     Abstract available


  5. METRA M, Tomasoni D, Adamo M, Anker SD, et al
    Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions.
    Circulation. 2025;151:1342-1363.
    PubMed     Abstract available


  6. MICHEL LYM, Esfahani H, De Mulder D, Verdoy R, et al
    An NRF2/beta3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress.
    Circulation. 2025;151:1312-1328.
    PubMed     Abstract available


    April 2025
  7. NAKAMORI S, Omori T, Fujimoto N, Ishida M, et al
    Interplay Between Epicardial Adipose Tissue and Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:1294-1296.
    PubMed    


  8. KHAN SS, Breathett K, Braun LT, Chow SL, et al
    Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2025 Apr 16. doi: 10.1161/CIR.0000000000001307.
    PubMed     Abstract available


  9. BUTLER J, Usman MS, Gandotra C, Salman A, et al
    Patient-Reported Outcomes as End Points in Heart Failure Trials.
    Circulation. 2025;151:1111-1125.
    PubMed     Abstract available


  10. OMLAND T, Mills NL
    Natriuretic Peptides for the Diagnosis of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:990-992.
    PubMed    


  11. GLARGAARD S, Hartvig Thomsen J, Tuxen C, Lindholm MG, et al
    A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
    Circulation. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.073521.
    PubMed     Abstract available


    March 2025
  12. EBERLY L, Tennison A, Morgan L, Smith M, et al
    Centering Dine (Navajo) Voices: Barriers, Facilitators, and Perceptions of Cardiac Care among Patients with Heart Failure in Rural Navajo Nation.
    Circulation. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.124.073166.
    PubMed     Abstract available


  13. KAR S, Makkar RR, Whisenant BK, Hamid N, et al
    Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial.
    Circulation. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074536.
    PubMed     Abstract available


  14. CHEN L, Hu Y, Saguner AM, Bauce B, et al
    Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy.
    Circulation. 2025 Mar 24. doi: 10.1161/CIRCULATIONAHA.124.072226.
    PubMed     Abstract available


  15. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2025;151:e763.
    PubMed    


  16. BASILE C, Lindberg F, Benson L, Guidetti F, et al
    Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction.
    Circulation. 2025 Mar 17. doi: 10.1161/CIRCULATIONAHA.124.072855.
    PubMed     Abstract available


  17. FILIPP M, Ge ZD, DeBerge M, Lantz C, et al
    Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.070248.
    PubMed     Abstract available


  18. DAI H, Lu X, Zhou X
    Letter by Dai et al Regarding Article, "Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction".
    Circulation. 2025;151:e686.
    PubMed    


  19. YANCY CW
    Heart Failure: A Century View, From Failure to Function.
    Circulation. 2025;151:585-588.
    PubMed    


    February 2025
  20. LIU X, Wang Q, Li X, Yang Y, et al
    Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA.
    Circulation. 2025 Feb 20. doi: 10.1161/CIRCULATIONAHA.124.070840.
    PubMed     Abstract available


  21. BRAUMANN S, Macherey-Meyer S, Polzin A, Costard-Jackle A, et al
    MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial.
    Circulation. 2025 Feb 12. doi: 10.1161/CIRCULATIONAHA.125.074085.
    PubMed    


  22. SHEN L, Jhund PS, McMurray JJV
    Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF".
    Circulation. 2025;151:e38.
    PubMed    


  23. TUNCEZ A, Gurses KM
    Letter by Tuncez and Gurses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF".
    Circulation. 2025;151:e37.
    PubMed    


    January 2025
  24. KUEHN BM
    Kidney Decline Predicts Worse Heart Failure Outcomes.
    Circulation. 2025;151:348-350.
    PubMed    


  25. REDDY YNV, Tada A, Obokata M, Carter RE, et al
    Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting.
    Circulation. 2025 Jan 22. doi: 10.1161/CIRCULATIONAHA.124.072156.
    PubMed     Abstract available


  26. PARK SJ, Kang DH
    Response by Park and Kang to Letter Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e28.
    PubMed    


  27. MORDI IR, McCrimmon RJ, Lang CC
    SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
    Circulation. 2025;151:199-201.
    PubMed    


  28. WANG J, Peng Y
    Letter by Wang and Peng Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e27.
    PubMed    


  29. DERKS W, Rode J, Collin S, Rost F, et al
    A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease.
    Circulation. 2025;151:245-256.
    PubMed     Abstract available


    December 2024
  30. YAMADA Y, Sadahiro T, Nakano K, Honda S, et al
    Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Dec 14. doi: 10.1161/CIRCULATIONAHA.123.067504.
    PubMed     Abstract available


  31. DOI SN, Butt JH, Thune JJ, Nielsen JC, et al
    Left Ventricular Ejection Fraction and Implantable Cardioverter-Defibrillator in Non-ischemic Heart Failure with Reduced Ejection Fraction: Insights from DANISH.
    Circulation. 2024 Dec 10. doi: 10.1161/CIRCULATIONAHA.124.071777.
    PubMed    


  32. ALVAREZ-GARCIA J
    Cognitive Dysfunction in Heart Failure With Preserved Ejection Fraction: Uncovering the Consequences of an Overlooked Comorbidity.
    Circulation. 2024;150:1928-1930.
    PubMed    


  33. YANG X, Zhang Z
    Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial".
    Circulation. 2024;150:e468.
    PubMed    


  34. SANDHU AT, Spertus JA, Heidenreich PA
    Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial".
    Circulation. 2024;150:e469-e470.
    PubMed    


    November 2024
  35. KEHR D, Ritterhoff J, Glaser M, Jarosch L, et al
    S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models.
    Circulation. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.066961.
    PubMed     Abstract available


  36. JI Y, Zhang MJ, Wang W, Norby FL, et al
    Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS.
    Circulation. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.124.070278.
    PubMed     Abstract available


  37. ZILE MR, Borlaug BA, Kramer CM, Baum SJ, et al
    Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity.
    Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072679.
    PubMed     Abstract available


  38. VOORRIPS SN, Westenbrink BD
    Ketone Treatment in Heart Failure With Preserved Ejection Fraction: Recharging the Heart or Reducing Filling Pressures?
    Circulation. 2024;150:1584-1587.
    PubMed    


    October 2024
  39. SHEN L, Dewan P, Ferreira JP, Cunningham JW, et al
    Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    Circulation. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070553.
    PubMed     Abstract available


  40. SOHNS C, Sommer P
    Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy.
    Circulation. 2024;150:1220-1222.
    PubMed    


  41. BEDIOUNE I, Gandon-Renard M, Dessillons M, Barthou A, et al
    Essential Role of the RIalpha Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development.
    Circulation. 2024 Oct 2. doi: 10.1161/CIRCULATIONAHA.124.068858.
    PubMed     Abstract available


  42. JIA K, Cheng H, Ma W, Zhuang L, et al
    RNA Helicase DDX5 Maintains Cardiac Function by Regulating CamkIIdelta Alternative Splicing.
    Circulation. 2024;150:1121-1139.
    PubMed     Abstract available


  43. KNEUER JM, Grajek IA, Winkler M, Erbe S, et al
    Novel Long Noncoding RNA HEAT4 Affects Monocyte Subtypes, Reducing Inflammation and Promoting Vascular Healing.
    Circulation. 2024;150:1101-1120.
    PubMed     Abstract available


    September 2024
  44. DOCHERTY KF, Henderson AD, Jhund PS, Claggett BL, et al
    Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial.
    Circulation. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011.
    PubMed     Abstract available


  45. VADUGANATHAN M, Claggett BL, Kulac IJ, Miao ZM, et al
    Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure.
    Circulation. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055.
    PubMed     Abstract available


  46. SHADDY R, Burch M, Kantor PF, Solar-Yohay S, et al
    Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
    Circulation. 2024 Sep 25. doi: 10.1161/CIRCULATIONAHA.123.066605.
    PubMed     Abstract available


  47. STONE GW, Lindenfeld J, Rodes-Cabau J, Anker SD, et al
    Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
    Circulation. 2024 Sep 23. doi: 10.1161/CIRCULATIONAHA.124.070870.
    PubMed     Abstract available


  48. WANG J, Chen B, Shi Q, Ciampa G, et al
    Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development.
    Circulation. 2024 Sep 18. doi: 10.1161/CIRCULATIONAHA.124.069329.
    PubMed     Abstract available



  49. Correction to: Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024;150:e268.
    PubMed    


  50. TANG WHW, Bakitas MA, Cheng XS, Fang JC, et al
    Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Sep 10. doi: 10.1161/CIR.0000000000001273.
    PubMed     Abstract available


  51. KOSIBOROD MN, Petrie MC, Borlaug BA
    Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial".
    Circulation. 2024;150:e226-e227.
    PubMed    


  52. WEIR RAP
    Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
    Circulation. 2024;150:e224-e225.
    PubMed    


  53. BUTT JH, McMurray JJ, Claggett BL, Jhund PS, et al
    Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials.
    Circulation. 2024 Sep 1. doi: 10.1161/CIRCULATIONAHA.124.071110.
    PubMed     Abstract available


    August 2024
  54. SOHNS C, Moersdorf M, Marrouche NF, Bergau L, et al
    Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation: Two-year Follow-up of the CASTLE-HTx Trial.
    Circulation. 2024 Aug 30. doi: 10.1161/CIRCULATIONAHA.124.071517.
    PubMed    


  55. GOPALASINGAM N, Berg-Hansen K, Christensen KH, Ladefoged BT, et al
    Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732.
    PubMed     Abstract available


  56. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial".
    Circulation. 2024;150:e107-e108.
    PubMed    


  57. WANG J
    Letter by Wang Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial".
    Circulation. 2024;150:e106.
    PubMed    


  58. GREENE SJ, Butler J, Fonarow GC
    Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles.
    Circulation. 2024;150:422-424.
    PubMed    


  59. NETUKA I, Tucanova Z, Ivak P, Gregor S, et al
    A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.
    Circulation. 2024;150:509-511.
    PubMed    


  60. TADA A, Burkhoff D, Naser JA, Harada T, et al
    Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial.
    Circulation. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.124.068788.
    PubMed     Abstract available


    July 2024
  61. ABOUMSALLEM JP, de Boer RA
    IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure.
    Circulation. 2024;150:390-392.
    PubMed    


  62. YOO SGK, Lam CSP, Sweitzer NK
    "Asian" Heart Failure.
    Circulation. 2024;150:177-179.
    PubMed    


  63. WEYRICH M, Cremer S, Gerster M, Sarakpi T, et al
    Loss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease.
    Circulation. 2024 Jul 15. doi: 10.1161/CIRCULATIONAHA.124.069139.
    PubMed     Abstract available


  64. KATOH M, Nomura S, Yamada S, Ito M, et al
    Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
    Circulation. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.064719.
    PubMed     Abstract available



  65. Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2024;150:e63.
    PubMed    


    June 2024
  66. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069340.
    PubMed     Abstract available


  67. NASER JA, Tada A, Harada T, Reddy YNV, et al
    Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024;149:2026-2028.
    PubMed    


  68. DEWAN P, Shen L, Pedro Ferreira J, Jhund PS, et al
    Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
    Circulation. 2024 Jun 6. doi: 10.1161/CIRCULATIONAHA.124.068774.
    PubMed     Abstract available


    May 2024
  69. AMDANI S, Conway J, George K, Martinez HR, et al
    Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2024 May 29. doi: 10.1161/CIR.0000000000001245.
    PubMed     Abstract available


  70. JHENG JR, Bai Y, Noda K, Huot JR, et al
    Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 May 28. doi: 10.1161/CIRCULATIONAHA.124.068624.
    PubMed     Abstract available


  71. CALLER T, Rotem I, Shaihov-Teper O, Lendengolts D, et al
    Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth.
    Circulation. 2024;149:1729-1748.
    PubMed     Abstract available


  72. PACKER M, Anker SD, Butler J, Cleland JGF, et al
    Redefining Iron Deficiency in Patients With Chronic Heart Failure.
    Circulation. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.068883.
    PubMed    


  73. SARMA S, Dyck JRB
    Unlocking Pathways That Improve Cardiac Function in Chronic Heart Failure: Are Ketones the Key?
    Circulation. 2024;149:1490-1492.
    PubMed    


  74. KANG DH, Park SJ, Shin SH, Hwang IC, et al
    Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
    Circulation. 2024 May 1. doi: 10.1161/CIRCULATIONAHA.124.069144.
    PubMed     Abstract available


    April 2024
  75. ZHANG F, Zhang L, Hu G, Chen X, et al
    Rectifying METTL4-Mediated N(6)-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure.
    Circulation. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.068358.
    PubMed     Abstract available


  76. LEMESLE G, Lamblin N, Schurtz G, Labreuche J, et al
    Comparison of Incidence and Prognostic Impact of Ischemic Major Bleeding and Heart Failure Events in Patients With Chronic Coronary Syndrome: Insights From the CORONOR Registry.
    Circulation. 2024 Apr 25. doi: 10.1161/CIRCULATIONAHA.123.067938.
    PubMed     Abstract available


  77. SWAIN L, Bhave S, Qiao X, Reyelt L, et al
    Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation.
    Circulation. 2024;149:1341-1353.
    PubMed     Abstract available



  78. Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2024;149:e1130.
    PubMed    


  79. LI B, Liu F, Chen X, Chen T, et al
    FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System.
    Circulation. 2024;149:1268-1284.
    PubMed     Abstract available


  80. SANDHU AT, Calma J, Skye M, Kalwani NM, et al
    Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624.
    PubMed     Abstract available


  81. HERNANDEZ AF, Udell JA, Jones WS, Anker SD, et al
    Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
    Circulation. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217.
    PubMed     Abstract available


  82. BREATHETT K, Lewsey S, Brownell NK, Enright K, et al
    Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Apr 3. doi: 10.1161/CIR.0000000000001231.
    PubMed     Abstract available



  83. Correction to: INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2024;149:e1066.
    PubMed    


  84. GOKULNATH P, Spanos M, Lehmann HI, Sheng Q, et al
    Distinct Plasma Extracellular Vesicle Transcriptomes in Acute Decompensated Heart Failure Subtypes: A Liquid Biopsy Approach.
    Circulation. 2024;149:1147-1149.
    PubMed    


  85. KAPELIOS CJ, Lund LH
    Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure.
    Circulation. 2024;149:1062-1064.
    PubMed    


    March 2024
  86. BERG-HANSEN K, Gopalasingam N, Christensen KH, Ladefoged B, et al
    Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
    Circulation. 2024 Mar 27. doi: 10.1161/CIRCULATIONAHA.123.067971.
    PubMed     Abstract available


  87. JESSUP M
    A Century of Heart Failure With Reduced Ejection Fraction: Mostly Drought, Followed by Rapid Progress.
    Circulation. 2024;149:899-901.
    PubMed    


  88. CLELAND JGF
    Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure.
    Circulation. 2024;149:839-842.
    PubMed    


  89. VELIKANOVA D, Poyhonen P, Lehtonen J, Simonen P, et al
    End-Stage Heart Failure in Cardiac Sarcoidosis.
    Circulation. 2024;149:885-887.
    PubMed    


    February 2024
  90. HOEDEMAKERS S, Pugliese NR, Stassen J, Vanoppen A, et al
    mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis.
    Circulation. 2024 Feb 27. doi: 10.1161/CIRCULATIONAHA.123.067130.
    PubMed     Abstract available


  91. CRESCI S, Bach RG, Saberi S, Owens AT, et al
    Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Circulation. 2024;149:498-509.
    PubMed     Abstract available


  92. GREEN JB, Everett BM, Ghosh A, Younes N, et al
    Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Circulation. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604.
    PubMed     Abstract available


  93. JIANG Y, Gu J, Niu X, Hu J, et al
    Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.067519.
    PubMed     Abstract available


  94. SANCHEZ RH, Hamdan H, Torrealba J, Grodin JL, et al
    Giants Hiding in Small Places: A Case of New Onset Heart Failure, Atrioventricular Block, and Ventricular Arrhythmias.
    Circulation. 2024;149:475-480.
    PubMed    


    January 2024
  95. HERWEG B, Sharma PS, Cano O, Ponnusamy SS, et al
    Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study.
    Circulation. 2024;149:379-390.
    PubMed     Abstract available


  96. SUMARSONO A, Xie L, Keshvani N, Zhang C, et al
    Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
    Circulation. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.067489.
    PubMed     Abstract available


  97. BROMAN MT, Nadadur RD, Perez-Cervantes C, Burnicka-Turek O, et al
    A Genomic Link From Heart Failure to Atrial Fibrillation Risk: FOG2 Modulates a TBX5/GATA4-Dependent Atrial Gene Regulatory Network.
    Circulation. 2024 Jan 8. doi: 10.1161/CIRCULATIONAHA.123.066804.
    PubMed     Abstract available


    December 2023
  98. REN Z, Zhao W, Li D, Yu P, et al
    INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065440.
    PubMed     Abstract available


  99. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    PubMed     Abstract available


  100. THOMPSON PD
    Steps May Count for More Than Just Cardiac Risk.
    Circulation. 2023;148:2017-2018.
    PubMed    


  101. GOSS KN
    Preterm Birth: An Overlooked Risk Factor for Heart Failure in the Young Adult.
    Circulation. 2023;148:2005-2007.
    PubMed    


  102. GOLDENBERG JR, Hays AG, Gabr RE, Sch?r M, et al
    Energetic Basis of Recovered Ejection Fraction in Human Heart Failure.
    Circulation. 2023;148:1976-1978.
    PubMed    


  103. VAN DUIJVENBODEN S, Ramirez J, Orini M, Aung N, et al
    Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects.
    Circulation. 2023;148:1932-1944.
    PubMed     Abstract available


  104. MCMURRAY JJV, Docherty KF, de Boer RA, Hammarstedt A, et al
    Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    Circulation. 2023 Dec 7. doi: 10.1161/CIRCULATIONAHA.123.065061.
    PubMed     Abstract available


    November 2023
  105. GREENE SJ, Butler J
    Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics.
    Circulation. 2023;148:1746-1749.
    PubMed    


  106. WALKER MA, Chen H, Yadav A, Ritterhoff J, et al
    Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation.
    Circulation. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039.
    PubMed     Abstract available


  107. XU W, Billon C, Li H, Wilderman A, et al
    Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
    Circulation. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542.
    PubMed     Abstract available


  108. WHELLAN DJ
    Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588.
    PubMed    


  109. VETROVSKY T, Siranec M, Frybova T, Gant I, et al
    Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395.
    PubMed     Abstract available


  110. KOSIBOROD MN, Verma S, Borlaug BA, Butler J, et al
    Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
    Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067505.
    PubMed     Abstract available


  111. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
    Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
    Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
    PubMed     Abstract available


  112. KHAN SS, Coresh J, Pencina MJ, Ndumele CE, et al
    Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.
    Circulation. 2023 Nov 10. doi: 10.1161/CIR.0000000000001191.
    PubMed     Abstract available


  113. KHAN SS, Matsushita K, Sang Y, Ballew SH, et al
    Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations.
    Circulation. 2023 Nov 10. doi: 10.1161/CIRCULATIONAHA.123.067626.
    PubMed     Abstract available


  114. BAWASKAR P, Thomas N, Ismail KF, Guo Y, et al
    Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease.
    Circulation. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067032.
    PubMed     Abstract available


    October 2023
  115. ZAMANI SK, Sarma S, MacNamara JP, Hynan LS, et al
    Excess Pericardial Fat Is Related to Adverse Cardio-Mechanical Interaction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023;148:1410-1412.
    PubMed    


  116. WAKEHAM DJ, Ivey E, Saland S, Lewis J, et al
    Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.066170.
    PubMed     Abstract available


  117. OSTROMINSKI JW, Vaduganathan M, Selvaraj S, Claggett BL, et al
    Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065254.
    PubMed     Abstract available


  118. BUTT JH, Yafasova A, Doi SN, Nielsen JC, et al
    Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial.
    Circulation. 2023;148:1179-1181.
    PubMed    


    September 2023
  119. GODFREY S, Kirkpatrick JN, Kramer DB, Sulistio MS, et al
    Expanding the Paradigm for Cardiovascular Palliative Care.
    Circulation. 2023;148:1039-1052.
    PubMed     Abstract available


  120. PARKASH R, O'Meara E, Tang ASL
    The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure.
    Circulation. 2023;148:933-935.
    PubMed    


  121. LEBEK S, Caravia XM, Chemello F, Tan W, et al
    Elimination of CaMKIIdelta Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice.
    Circulation. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117.
    PubMed     Abstract available


  122. COCHRAN J, Yura Y, Thel MC, Doviak H, et al
    Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170.
    PubMed     Abstract available


  123. CHEW DS, Li Y, Bigelow R, Cowper PA, et al
    Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
    Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602.
    PubMed     Abstract available


  124. ZHU H, Song YC, Hang PZ
    Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:855-856.
    PubMed    


  125. ARONSEN JM, Skogestad J, Albert I, Melleby AO, et al
    Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:857-858.
    PubMed    


    August 2023
  126. HEIDENREICH P
    What Is a Normal Left Ventricular Ejection Fraction?
    Circulation. 2023;148:750-752.
    PubMed    


  127. CHATUR S, Vaduganathan M, Claggett BL, Cunningham JW, et al
    Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
    Circulation. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506.
    PubMed     Abstract available


  128. PACKER M, Butler J, Zeller C, Pocock SJ, et al
    Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Circulation. 2023 Aug 24. doi: 10.1161/CIRCULATIONAHA.123.065748.
    PubMed    



  129. Correction to: Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
    Circulation. 2023;148:e7.
    PubMed    


  130. SARMA S, Levine BD
    Response by Sarma and Levine to Letters Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:620-621.
    PubMed    


  131. WUSSLER D, Belkin M, Mueller C
    Letter by Wussler et al Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:619.
    PubMed    


  132. RAGONE I, Barallobre-Barreiro J, Takov K, Theofilatos K, et al
    SERCA2a Protein Levels Are Unaltered in Human Heart Failure.
    Circulation. 2023;148:613-616.
    PubMed    


  133. DIMOPOULOS S, Nanas S
    Letter by Dimopoulos and Nanas Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:617-618.
    PubMed    


  134. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
    Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
    PubMed     Abstract available


    July 2023
  135. PACKER M, Wilcox CS, Testani JM
    Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Circulation. 2023;148:354-372.
    PubMed     Abstract available


  136. MENTIAS A, Mujahid MS, Sumarsono A, Nelson RK, et al
    Historical Redlining, Socioeconomic Distress, and Risk of Heart Failure Among Medicare Beneficiaries.
    Circulation. 2023;148:210-219.
    PubMed     Abstract available


  137. WATSON WD, Green PG, Lewis AJM, Arvidsson P, et al
    Retained Metabolic Flexibility of the Failing Human Heart.
    Circulation. 2023;148:109-123.
    PubMed     Abstract available


  138. GHADIMI K, Cappiello JL, Wright MC, Levy JH, et al
    Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
    Circulation. 2023 Jul 4. doi: 10.1161/CIRCULATIONAHA.122.062464.
    PubMed     Abstract available


    June 2023
  139. KONDO T, Dewan P, Anand IS, Desai AS, et al
    Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
    Circulation. 2023 Jun 27. doi: 10.1161/CIRCULATIONAHA.122.063642.
    PubMed     Abstract available


  140. HITSUMOTO T, Tsukamoto O, Matsuoka K, Li J, et al
    Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin.
    Circulation. 2023;147:1902-1918.
    PubMed     Abstract available


    May 2023
  141. TANG Y, Feng M, Su Y, Ma T, et al
    Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
    Circulation. 2023;147:1684-1704.
    PubMed     Abstract available


  142. GREENE SJ, Velazquez EJ, Anstrom KJ, Clare RM, et al
    Effect of Torsemide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
    Circulation. 2023 May 22. doi: 10.1161/CIRCULATIONAHA.123.064842.
    PubMed     Abstract available


  143. JANI V, Aslam MI, Fenwick AJ, Ma W, et al
    Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension.
    Circulation. 2023 May 17. doi: 10.1161/CIRCULATIONAHA.123.064717.
    PubMed     Abstract available


  144. GUPTA K, Spertus JA, Birmingham M, Gosch KL, et al
    Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
    Circulation. 2023 May 16. doi: 10.1161/CIRCULATIONAHA.122.063263.
    PubMed     Abstract available


  145. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    PubMed     Abstract available


    April 2023
  146. HUNDERTMARK MJ, Adler A, Antoniades C, Coleman R, et al
    Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
    Circulation. 2023 Apr 18. doi: 10.1161/CIRCULATIONAHA.122.062021.
    PubMed     Abstract available


  147. BUTLER J, Talha KM, Fonarow GC
    STRONG-HF and Implementing Heart Failure Therapies: Godspeed ... With Care.
    Circulation. 2023;147:1189-1191.
    PubMed    


  148. FILIPPATOS G, Ponikowski P, Farmakis D, Anker SD, et al
    Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Circulation. 2023 Apr 13. doi: 10.1161/CIRCULATIONAHA.122.060757.
    PubMed     Abstract available


  149. ERN YEOH S, Docherty KF, Campbell RT, Jhund PS, et al
    Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Circulation. 2023 Apr 11. doi: 10.1161/CIRCULATIONAHA.122.063327.
    PubMed     Abstract available


  150. MENTIAS A, Peterson ED, Keshvani N, Kumbhani DJ, et al
    Achieving Equity in Hospital Performance Assessments Using Composite Race-Specific Measures of Risk-Standardized Readmission and Mortality Rates for Heart Failure.
    Circulation. 2023;147:1121-1133.
    PubMed     Abstract available



  151. Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2023;147:e674.
    PubMed    


  152. BUTT JH, Solomon SD, McMurray JJV
    Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1119-1120.
    PubMed    


  153. WONG EKC, Demers C
    Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1118.
    PubMed    


    March 2023
  154. SACHDEV V, Sharma K, Keteyian SJ, Alcain CF, et al
    Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Circulation. 2023 Mar 21. doi: 10.1161/CIR.0000000000001122.
    PubMed     Abstract available


  155. SELVARAJ S, Kosiborod MN, Shah SH
    Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:922-923.
    PubMed    


  156. TACHIBANA S, Yu NK, Li R, Fernandez-Costa C, et al
    Perm1 Protects the Heart From Pressure Overload-Induced Dysfunction by Promoting Oxidative Metabolism.
    Circulation. 2023;147:916-919.
    PubMed    


  157. MONZO L, Melenovsky V
    Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:920-921.
    PubMed    


  158. MENG Z, Zhang Z, Zhao J, Liu C, et al
    Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
    PubMed     Abstract available


  159. KUEHN BM
    Collaborative Care Model Helps Patients With Heart Failure Meet End-of-Life Goals.
    Circulation. 2023;147:841-842.
    PubMed    


  160. FRIEDMAN DJ, Al-Khatib SM, Dalgaard F, Fudim M, et al
    Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.
    Circulation. 2023;147:812-823.
    PubMed     Abstract available


  161. SKOGESTAD J, Albert I, Hougen K, Lothe GB, et al
    Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.121.054168.
    PubMed     Abstract available


  162. KONDO T, Jering KS, Borleffs CJW, de Boer RA, et al
    Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.122.062918.
    PubMed     Abstract available


  163. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    PubMed     Abstract available


    February 2023
  164. LEYVA F, Israel CW, Singh J
    Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Circulation. 2023;147:759-767.
    PubMed     Abstract available


    December 2022
  165. SHELBAYA K, Claggett B, Dorbala P, Skali H, et al
    Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061396.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.